---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-085399"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:47:18.282391+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences reports FY2025 net loss of $119.9M; cash $256M, outlines dabogratinib 3x3 strategy

## Summary
- Q4 2025 net loss $33.8M vs $25.6M; FY net loss $119.9M vs $86.5M; R&D spend rose to $102.9M.
- Cash, equivalents and marketable securities $256.0M at Dec 31, 2025; runway through at least 2027.
- Launched 'dabogratinib 3x3' strategy: three pivotal-ready studies in LG-UTUC, IR NMIBC, and ACH.
- SURF302 (IR NMIBC) initial 3-month CR data expected by end 1H 2026; BEACH301 (ACH) interim results 2H 2026.
- Appointed Bhavesh Ashar as COO and Heather Faulds as Chief Regulatory Officer in Q4 2025.

## SEC filing metadata
- accession: 0001193125-26-085399
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/0001193125-26-085399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/tyra-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-085399
- JSON: https://secwatch.observer/filing/0001193125-26-085399.json
- Plain text: https://secwatch.observer/filing/0001193125-26-085399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.